Newsroom

Views and missives from the frontier

All
  • Press Releases
  • Perspectives
  • In the News
  • Videos
    • Perspectives Headshot

    Perspectives

    EPIC proportions of discovery: CAMP4’s AI model for identifying regRNA targets

    Yuchun Guo, Ph.D. & Yuting Liu, Ph.D.

    Finding light in the dark side of the genome: CAMP4’s approach to targeting regRNA in genetic diseases

    Alfica Seghal, Ph.D.
    Read All Perspectives

    Bringing Light to the Dark Side of the Genome

    CAMP4 is pioneering drug development targeting regulatory RNAs, the next frontier in the non-coding genome. Our ongoing series on the “dark genome” explains this new area of biology, our approach, and the vast potential of our platform to create medicines that solve to address thousands of genetic diseases.

    The Dark Genome: The Next Frontier

    By targeting the regulatory components of transcription that play a central role in gene expression, CAMP4 has opened a new area of biology for drug discovery.

    Featuring:

    Benjamin Neale, Ph.D., David Bumcrot, Ph.D., Richard Young, Ph.D., Ann Barbier, M.D., Ph.D.

    AI + Genetics: Unlocking Vast Possibilities

    Combining the power of AI with proprietary, high-quality data sets, CAMP4 is illuminating the dark side of the genome.

    Featuring:

    David Bumcrot, Ph.D., Benjamin Neale, Ph.D.

    Turning Gene Control Into Patient Impact

    Controlling gene expression by targeting regRNAs offers enormous potential to help patients across a wide range of genetic diseases.

    Featuring:

    Richard Young, Ph.D., Alfica Sehgal, Ph.D., Josh Mandel-Brehm, Benjamin Neale, Ph.D.
    Top